Omnio Healer Seals Partnership Agreement With Eden Biodesign

Omnio Healer has entered into a partnership agreement with Eden Biodesign. Under the agreement, Eden Biodesign will provide process development and cGMP production services relating to Omnio Healer’s lead recombinant protein candidate.

Reportedly, the agreement with Eden Biodesign relates to the expression of proteins using mammalian cell culture for use against several clinical indications, but primarily for studies relating to chronic eardrum wounds.

Eden Biodesign would undertake the development of a robust manufacturing process for the product leading to cGMP production for supplying clinical studies.

Moreover, the company has also assessed Eden Biodesign as a potential future commercial manufacturer of the product, using its MHRA-inspected cGMP manufacturing facilities located in Liverpool, UK.

Mats Stromqvist, CEO of Omnio Healer, said: “Our protein product has shown very promising preclinical results in wound healing indications. We are now very keen to take the next step and gain access to GMP-material for use in clinical trials. At the same time, we have every confidence that Eden Biodesign will become a valuable partner in this regard, providing both cGMP process development and production.”